UroGen Pharma Faces Scrutiny as Lawsuit Investigations Intensify

UroGen Pharma shares are trading lower after Pomerantz Law Firm announced an investigation into potential securities fraud, coupled with FDA concerns over trial design for its bladder cancer drug.